Biosion is a global clinical-stage biotechnology company focused on developing innovative antibody-based therapies to improve outcomes for patients with immune and oncologic diseases.
Biosion is a global clinical-stage biotechnology company focused on developing innovative antibody-based therapies to improve outcomes for patients with immune and oncologic diseases. Leveraging its proprietary technologies such as the H³ antibody discovery platform, SynTracer® HT endocytosis platform, and Flexibody® bispecific platform, Biosion creates highly differentiated medicines to address significant unmet medical needs worldwide. With its"discover-development-partnership"model, the company has forged 10 global collaborations, advancing 9 clinical-stage assets, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates. Biosion operates across the US, China, and Australia.
Corporate Culture
Mission
To discover and develop innovative biologics through the synergy of great science, cutting edge technologies and superior craftsmanship for patients worldwide.
Vision
Delivering Breakthrough Antibody-Based Therapeutics to Patients Globally
